Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis

Use of a combination of Cladribine and IFN-beta for making a medicament for treating patients suffering from multiple sclerosis and who have received at least difficult one conventional therapy for multiple sclerosis, wherein Cladribine is to be orally administered following the sequential: i) The initial period wherein Cladribine is to be take and wherein the total dose of Cladribine reached at the end of the initial period is from about 1.7 mg / kg to about 3.5 mg / kg and ii) period without taking Cladribine, wherein Cladribine is not to be taken; iii) A maintenance period wherein Cladribine is to be taken and wherein the total dose of Cladribine to be taken during the maintenance period is lower than or equal to a total dose of Cladribine dostignutoj at the end of the initial period (i), iv) taking the Cladribine-free period, wherein Cladribine is to be not more uzeti.Prijava contains 25 claims.